Episode
Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
- Podcast
- Business Of Biotech
- Published
- Mar 16, 2026
- Duration seconds
- 3240
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-cns-cancers-with-plus-therapeutics-marc-hedrick-m-d.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq. We'll talk about Plus Therapeutics' diagnostic subsidiary, CNSide, and hear from Marc about recent FDA meetings and the ...